- Home
- GUG vs ORGO Comparison
GUG vs ORGO Comparison
Compare GUG & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUG
- ORGO
- Stock Information
- Founded
- GUG 2021
- ORGO 1985
- Country
- GUG United States
- ORGO United States
- Employees
- GUG N/A
- ORGO N/A
- Industry
- GUG Trusts Except Educational Religious and Charitable
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- GUG Finance
- ORGO Health Care
- Exchange
- GUG Nasdaq
- ORGO Nasdaq
- Market Cap
- GUG 470.0M
- ORGO 465.6M
- IPO Year
- GUG N/A
- ORGO N/A
- Fundamental
- Price
- GUG $15.38
- ORGO $4.98
- Analyst Decision
- GUG
- ORGO Buy
- Analyst Count
- GUG 0
- ORGO 2
- Target Price
- GUG N/A
- ORGO $6.50
- AVG Volume (30 Days)
- GUG 108.9K
- ORGO 997.1K
- Earning Date
- GUG 01-01-0001
- ORGO 08-07-2025
- Dividend Yield
- GUG 9.67%
- ORGO N/A
- EPS Growth
- GUG N/A
- ORGO N/A
- EPS
- GUG N/A
- ORGO N/A
- Revenue
- GUG N/A
- ORGO $458,760,000.00
- Revenue This Year
- GUG N/A
- ORGO $1.10
- Revenue Next Year
- GUG N/A
- ORGO $9.93
- P/E Ratio
- GUG N/A
- ORGO N/A
- Revenue Growth
- GUG N/A
- ORGO 5.35
- 52 Week Low
- GUG $12.71
- ORGO $2.28
- 52 Week High
- GUG $15.06
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- GUG 49.61
- ORGO 69.16
- Support Level
- GUG $15.17
- ORGO $4.30
- Resistance Level
- GUG $15.43
- ORGO $4.53
- Average True Range (ATR)
- GUG 0.19
- ORGO 0.27
- MACD
- GUG -0.03
- ORGO 0.05
- Stochastic Oscillator
- GUG 30.00
- ORGO 97.19
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.